Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Russell Esterline"'
Autor:
Sven O. Göpel, Damilola Adingupu, Jue Wang, Elizaveta Semenova, Margareta Behrendt, Rasmus Jansson-Löfmark, Christine Ahlström, Ann-Cathrine Jönsson-Rylander, V. Sashi Gopaul, Russell Esterline, Li-Ming Gan, Rui-Ping Xiao
Publikováno v:
Cardiovascular Diabetology, Vol 23, Iss 1, Pp 1-15 (2024)
Abstract Background SGLT2 inhibitors, a T2DM medication to lower blood glucose, markedly improve cardiovascular outcomes but the underlying mechanism(s) are not fully understood. SGLT2i’s produce a unique metabolic pattern by lowering blood glucose
Externí odkaz:
https://doaj.org/article/e4b485641d78496b9714711ae24f8c10
Autor:
Yvo J.M. op den Kamp, Anne Gemmink, Marlies de Ligt, Bas Dautzenberg, Esther Kornips, Johanna A. Jorgensen, Gert Schaart, Russell Esterline, Diego A. Pava, Joris Hoeks, Vera B. Schrauwen-Hinderling, Sander Kersten, Bas Havekes, Timothy R. Koves, Deborah M. Muoio, Matthijs K.C. Hesselink, Jan Oscarsson, Esther Phielix, Patrick Schrauwen
Publikováno v:
Molecular Metabolism, Vol 66, Iss , Pp 101620- (2022)
Objective: SGLT2 inhibitors increase urinary glucose excretion and have beneficial effects on cardiovascular and renal outcomes; the underlying mechanism may be metabolic adaptations due to urinary glucose loss. Here, we investigated the cellular and
Externí odkaz:
https://doaj.org/article/ce94ee3f45bd45f3ad7d1120c2287583
Autor:
Samvel B. Gasparyan, Joan Buenconsejo, Elaine K. Kowalewski, Jan Oscarsson, Olof F. Bengtsson, Russell Esterline, Gary G. Koch, Otavio Berwanger, Mikhail N. Kosiborod
Publikováno v:
Therapeutic Innovation & Regulatory Science. 56:785-794
DARE-19 (NCT04350593) was a randomized trial studying the effects of dapagliflozin, an SGLT2 inhibitor, in hospitalized patients with COVID-19 pneumonia and cardiometabolic risk factors. The conduct of DARE-19 offered the opportunity to define an inn
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5814f91c918ca67c5cd54afbf7b8659
https://doi.org/10.1007/s43441-022-00420-1
https://doi.org/10.1007/s43441-022-00420-1
Autor:
Hiddo J.L. Heerspink, Remo H.M. Furtado, Otavio Berwanger, Gary G. Koch, Felipe Martinez, Omar Mukhtar, Subodh Verma, Samvel B. Gasparyan, Fengming Tang, Sheryl L. Windsor, Vicente Cés de Souza-Dantas, Mildren del Sueldo, Robert Frankel, Ali Javaheri, Rafael A. Maldonado, Caryn Morse, Marco Mota-Gomes, Douglas Shemin, Osvaldo Lourenço Silva, Alexandre Pereira Tognon, Marcel Twahirwa, Joan Buenconsejo, Russell Esterline, Jan Oscarsson, Philip Ambery, Anna Maria Langkilde, Mikhail N. Kosiborod
Publikováno v:
Clinical Journal of the American Society of Nephrology, 17(5), 643-654. AMER SOC NEPHROLOGY
Background and objectives: Patients who were hospitalized with coronavirus disease 2019 (COVID-19) infection are at high risk of AKI and KRT, especially in the presence of CKD. The Dapagliflozin in Respiratory Failure in Patients with COVID-19 (DARE-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c491a2678c9f1ac2ef6cc16352edbba7
https://hdl.handle.net/11370/16474bfb-657f-4bed-8cc4-7901430ed11b
https://hdl.handle.net/11370/16474bfb-657f-4bed-8cc4-7901430ed11b
Autor:
Jan Oscarsson, Emily E Akin, Ali Javaheri, Diogo D.F. Moia, Russell Esterline, Fengming Tang, Gary G. Koch, Audes D. M. Feitosa, Robert Gordon, Samvel B. Gasparyan, Joan Buenconsejo, Cristiano P Jaeger, Weimar Kunz Sebba Barroso, Philip Ambery, Omar Mukhtar, Paulo Leães, Anna Maria Langkilde, Subodh Verma, Conrado R. Hoffmann Filho, Ronaldo V P Soares, Kensey Gosch, Lilia Nigro Maia, Michael Pursley, Otavio Berwanger, Michael E. Nassif, Sheryl L. Windsor, Mikhail Kosiborod, José Roberto Lazcano Soto, Felipe Martinez, Vijay K. Chopra, Remo H.M. Furtado, Matthew Aboudara, Fabio Serra Silveira, Alberto Fonseca, Vishnu Garla
Publikováno v:
The Lancet. Diabetes & Endocrinology
Summary Background COVID-19 can lead to multiorgan failure. Dapagliflozin, a SGLT2 inhibitor, has significant protective benefits for the heart and kidney. We aimed to see whether this agent might provide organ protection in patients with COVID-19 by
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13309fb301d8f869f6b911b980626f4b
https://doi.org/10.1016/s2213-8587(21)00180-7
https://doi.org/10.1016/s2213-8587(21)00180-7
Autor:
Anna Veelen, Charlotte Andriessen, Yvo Op den Kamp, Edmundo Erazo-Tapia, Marlies de Ligt, Julian Mevenkamp, Johanna A. Jörgensen, Esther Moonen-Kornips, Gert Schaart, Russell Esterline, Bas Havekes, Jan Oscarsson, Vera B. Schrauwen-Hinderling, Esther Phielix, Patrick Schrauwen
Publikováno v:
Metabolism-Clinical and Experimental. W B Saunders Co-Elsevier Inc
AIMS/HYPOTHESIS: Sodium-glucose cotransporter 2 inhibitor (SGLT2i) treatment in type 2 diabetes mellitus patients results in glucosuria, causing an energy loss, and triggers beneficial metabolic adaptations. It is so far unknown if SGLT2i exerts bene
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e1b25085fd23df1dc279992688641a1
https://pubmed.ncbi.nlm.nih.gov/36592688
https://pubmed.ncbi.nlm.nih.gov/36592688
Autor:
Elmar Zügner, Hsiu-Chiung Yang, Petra Kotzbeck, Beate Boulgaropoulos, Harald Sourij, Sepideh Hagvall, Charles S. Elmore, Russell Esterline, Sven Moosmang, Jan Oscarsson, Thomas R. Pieber, Xiao-Rong Peng, Christoph Magnes
Publikováno v:
International Journal of Molecular Sciences; Volume 23; Issue 14; Pages: 7966
(1) The cardio-reno-metabolic benefits of the SGLT2 inhibitors canagliflozin (cana), dapagliflozin (dapa), ertugliflozin (ertu), and empagliflozin (empa) have been demonstrated, but it remains unclear whether they exert different off-target effects i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::077568d1b6dab0b11bcd16983a9fe3a4
Autor:
Axel Åkerblom, Kerstin Heurling, Eleni Rebelos, Jan Oscarsson, Edvin Johansson, Sanna Laurila, Henrik Isackson, Aino Latva-Rasku, Jonas Oldgren, Maria Saarenhovi, Olof Eriksson, Ele Ferrannini, Ulrica Wilderäng, Pirjo Nuutila, Russell Esterline, Cecilia Karlsson
Publikováno v:
Diabetes, Obesity and Metabolism. 23:1505-1517
Aim To explore the early effects of dapagliflozin on myocardial function and metabolism in patients with type 2 diabetes without heart failure. Materials and methods Patients with type 2 diabetes on metformin treatment were randomized to double-blind
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f009b0cfaf2454565ffd8cd35f2de43
https://doi.org/10.1111/dom.14363
https://doi.org/10.1111/dom.14363
Autor:
Otavio Berwanger, Jan Oscarsson, Samvel B. Gasparyan, Joan Buenconsejo, Anna Maria Langkilde, Russell Esterline, Gary G. Koch, Mikhail Kosiborod, Philip Ambery, C. David Sjöström, Omar Mukhtar, Subodh Verma, Ali Javaheri, Felipe Martinez, Vijay K. Chopra
Publikováno v:
Diabetes, Obesity and Metabolism. 23:886-896
AIMS: Coronavirus disease 2019 (COVID-19) is caused by a novel severe acute respiratory syndrome coronavirus 2. It can lead to multiorgan failure, including respiratory and cardiovascular decompensation, and kidney injury, with significant associated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::434bd1fd0b5b5a7b066933513e0641dd
https://doi.org/10.1111/dom.14296
https://doi.org/10.1111/dom.14296
Autor:
Carla Valenzuela Ripoll, Zhen Guo, Tripti Kumari, Kana N. Miyata, Mualla Ozcan, Ahmed Diab, Amanda Girardi, Li He, Attila Kovacs, Carla Weinheimer, Jess Nigro, Jan Oscarsson, Russell Esterline, Joel Schilling, Mikhail Kosiborod, Christina Christoffersen, Jaehyung Cho, Ali Javaheri
RationaleSodium-glucose co-transporter inhibitors (SGLT2i) are under active clinical investigation in patients with acute inflammatory conditions, based on their clinical cardio-and nephroprotective effects, and a pre-clinical study that demonstrated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::25e80a2c0a6c6c6ee9589a9e2c054527
https://doi.org/10.1101/2022.04.27.489709
https://doi.org/10.1101/2022.04.27.489709
